BiotechTube

Levalbuterol HCl Inhalation Solution + Levalbuterol HCl Inhalation Solution + Albuterol HCl Inhalation Solution

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Reactive Airways Disease (RAD)

Conditions

Reactive Airways Disease (RAD)

Trial Timeline

Feb 1, 2001 → Jul 1, 2002

NCT ID
NCT00685126

About Levalbuterol HCl Inhalation Solution + Levalbuterol HCl Inhalation Solution + Albuterol HCl Inhalation Solution

Levalbuterol HCl Inhalation Solution + Levalbuterol HCl Inhalation Solution + Albuterol HCl Inhalation Solution is a phase 3 stage product being developed by Sumitomo Pharma for Reactive Airways Disease (RAD). The current trial status is completed. This product is registered under clinical trial identifier NCT00685126. Target conditions include Reactive Airways Disease (RAD).

What happened to similar drugs?

1 of 2 similar drugs in Reactive Airways Disease (RAD) were approved

Approved (1) Terminated (1) Active (0)
✅Sitagliptin phosphate + PlaceboMerckApproved
❌RosuvastatinAstraZenecaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00685126Phase 3Completed

Competing Products

2 competing products in Reactive Airways Disease (RAD)

See all competitors
ProductCompanyStageHype Score
RosuvastatinAstraZenecaPhase 3
32
Sitagliptin phosphate + PlaceboMerckApproved
43